NCT05571839

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

A Phase 1 Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 41 (actual)
• Sponsor: Seagen, a wholly owned subsidiary of Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will test the safety of a drug called PF-08046049/SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. This study will have 3 parts. Parts A and B of the study will find out how much PF-08046049/SGN-BB228 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046049/SGN-BB228 is safe and if it works to treat solid tumor cancers.

Conditions

• Cutaneous Melanoma
• Non-small Cell Lung Cancer
• Colorectal Neoplasms
• Pancreatic Neoplasms
• Mesothelioma

Interventions

Type	Name	Description
DRUG	PF-08046049	Given into the vein (IV; intravenous)

Timeline

• Start date: 2023-01-03
• Primary completion: 2026-06-06
• Completion: 2026-06-06
• First posted: 2022-10-07
• Last updated: 2026-04-07

Locations

36 sites across 6 countries: United States, Canada, France, Germany, Switzerland, United Kingdom

Regulatory

• FDA-regulated drug study